Is postoperative radiotherapy effective in patients with completely resected pathologic stage IIIA(N2) non-small cell lung cancer? High-risk populations should consider it

IF 2.7 3区医学 Q3 ONCOLOGY

Clinical and Translational Radiation Oncology Pub Date : 2024-11-17 DOI:10.1016/j.ctro.2024.100889

Shu-Xian Zhang , Chen-Chen Zhang , Run-Ping Hou , Xu-Wei Cai , Jun Liu , Wen Yu , Qin Zhang , Jin-Dong Guo , Chang-Lu Wang , Hong-Xuan Li , Zheng-Fei Zhu , Xiao-Long Fu , Wen Feng

{"title":"Is postoperative radiotherapy effective in patients with completely resected pathologic stage IIIA(N2) non-small cell lung cancer? High-risk populations should consider it","authors":"Shu-Xian Zhang , Chen-Chen Zhang , Run-Ping Hou , Xu-Wei Cai , Jun Liu , Wen Yu , Qin Zhang , Jin-Dong Guo , Chang-Lu Wang , Hong-Xuan Li , Zheng-Fei Zhu , Xiao-Long Fu , Wen Feng","doi":"10.1016/j.ctro.2024.100889","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and purpose</h3><div>We aimed to assess the benefits of postoperative radiotherapy (PORT) in completely resected patients with pathologic stage IIIA(N2) non-small cell lung cancer (NSCLC) with a high risk of locoregional recurrence (LRR).</div></div><div><h3>Materials and methods</h3><div>A prospective, randomized trial was conducted starting in July 2016 to explore the optimal timing of PORT in high-LRR-risk patients with completely resected IIIA(N2) NSCLC (NCT02974426). Patients were identified as high-LRR-risk patients via the prognostic index (PI) model and were randomly assigned to PORT-first or PORT-last treatment. To evaluate PORT for high-LRR-risk patients, all patients in this trial constituted the PORT cohort, whereas high-LRR-risk patients without PORT were selected from a retrospective cohort as the non-PORT cohort. Propensity score-matched (PSM) analyses were conducted to compare overall survival (OS), disease-free survival (DFS), locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS).</div></div><div><h3>Results</h3><div>Between 2016 and 2022, 132 patients were included in the trial, with a median follow-up of 49.3 months. The 3-year OS rate was 83.2 %, and the 3-year DFS rate was 35.0 %. Among these patients, 122 patients (92 %) received planned PORT. For 132 intention-to-treat patients, PSM analysis with the non-PORT cohort (n = 307) resulted in 130 matched pairs. The results revealed that PORT improved LRFS (3-year LRFS, 77.6 % vs. 57.3 %; p = 0.00014), DFS (3-year DFS, 35.2 % vs. 28.6 %; p = 0.038), and OS (3-year OS, 83.0 % vs. 60.7 %; p = 0.00017), with no difference in DMFS (p = 0.17).</div></div><div><h3>Conclusion</h3><div>PORT could increase local control, DFS, and OS in high-LRR-risk patients with completely resected IIIA(N2) NSCLC. Future research should utilize multidimensional data to pinpoint more precise subgroups benefiting from PORT, with prospective trials validating these findings.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100889"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405630824001666","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose

We aimed to assess the benefits of postoperative radiotherapy (PORT) in completely resected patients with pathologic stage IIIA(N2) non-small cell lung cancer (NSCLC) with a high risk of locoregional recurrence (LRR).

Materials and methods

A prospective, randomized trial was conducted starting in July 2016 to explore the optimal timing of PORT in high-LRR-risk patients with completely resected IIIA(N2) NSCLC (NCT02974426). Patients were identified as high-LRR-risk patients via the prognostic index (PI) model and were randomly assigned to PORT-first or PORT-last treatment. To evaluate PORT for high-LRR-risk patients, all patients in this trial constituted the PORT cohort, whereas high-LRR-risk patients without PORT were selected from a retrospective cohort as the non-PORT cohort. Propensity score-matched (PSM) analyses were conducted to compare overall survival (OS), disease-free survival (DFS), locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS).

Results

Between 2016 and 2022, 132 patients were included in the trial, with a median follow-up of 49.3 months. The 3-year OS rate was 83.2 %, and the 3-year DFS rate was 35.0 %. Among these patients, 122 patients (92 %) received planned PORT. For 132 intention-to-treat patients, PSM analysis with the non-PORT cohort (n = 307) resulted in 130 matched pairs. The results revealed that PORT improved LRFS (3-year LRFS, 77.6 % vs. 57.3 %; p = 0.00014), DFS (3-year DFS, 35.2 % vs. 28.6 %; p = 0.038), and OS (3-year OS, 83.0 % vs. 60.7 %; p = 0.00017), with no difference in DMFS (p = 0.17).

Conclusion

PORT could increase local control, DFS, and OS in high-LRR-risk patients with completely resected IIIA(N2) NSCLC. Future research should utilize multidimensional data to pinpoint more precise subgroups benefiting from PORT, with prospective trials validating these findings.

查看原文本刊更多论文

完全切除的病理分期 IIIA（N2）非小细胞肺癌患者术后放疗有效吗？高危人群应考虑

背景和目的我们旨在评估术后放疗（PORT）对完全切除的病理IIIA（N2）期非小细胞肺癌（NSCLC）患者的益处，这些患者具有较高的局部复发（LRR）风险。材料和方法自2016年7月起开展了一项前瞻性随机试验，以探索完全切除的IIIA（N2）期NSCLC高LRR风险患者PORT的最佳时机（NCT02974426）。患者通过预后指数（PI）模型被确定为高LRR风险患者，并随机分配到PORT-first或PORT-last治疗。为评估高 LRR 风险患者的 PORT 治疗效果，该试验中的所有患者构成 PORT 队列，而未接受 PORT 治疗的高 LRR 风险患者则从回顾性队列中选出，作为非 PORT 队列。进行倾向评分匹配（PSM）分析，比较总生存期（OS）、无病生存期（DFS）、无局部复发生存期（LRFS）和无远处转移生存期（DMFS）。结果2016年至2022年间，共有132名患者纳入试验，中位随访时间为49.3个月。3年OS率为83.2%，3年DFS率为35.0%。其中，122 名患者（92%）接受了计划的 PORT 治疗。对于 132 例意向治疗患者，通过与非 PORT 患者队列（n = 307）进行 PSM 分析，得出 130 对匹配患者。结果显示，PORT 改善了 LRFS（3 年 LRFS，77.6 % vs. 57.3 %；p = 0.00014）、DFS（3 年 DFS，35.2 % vs. 28.6 %；p = 0.038）和 OS（3 年 OS，83.0 % vs. 60.结论PORT可以增加完全切除的IIIA（N2）NSCLC高LRR风险患者的局部控制、DFS和OS。未来的研究应利用多维数据更精确地确定受益于PORT的亚组，并通过前瞻性试验验证这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊